Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Source: View publication →
In high-risk hypertensive patients, an amlodipine-based regimen (adding perindopril as needed) prevented more major cardiovascular events, strokes, and all-cause mortality, and induced less new-onset diabetes, compared with a traditional atenolol-based regimen (adding bendroflumethiazide as needed).
Key Findings
Study Design
Study Limitations
Clinical Significance
ASCOT-BPLA was a landmark trial that catalyzed a global shift in hypertension management guidelines. It provided definitive evidence against the traditional use of beta-blockers (like atenolol) and thiazides as a preferred first-line combination for uncomplicated hypertension, demonstrating that newer agents (calcium channel blockers plus ACE inhibitors) offer superior cardiovascular protection and metabolic safety.
Historical Context
For decades prior to this trial, beta-blockers and thiazide diuretics were the unquestioned standard of care for initial hypertension management based on early outcome trials. ASCOT-BPLA was designed to directly compare this older strategy against a newer regimen of a dihydropyridine calcium channel blocker and an ACE inhibitor. Published in 2005, its findings led major guideline bodies (e.g., NICE in the UK) to controversially but permanently demote beta-blockers from routine first-line therapy for essential hypertension.
Guided Discussion
High-yield insights from every perspective
Based on the mechanisms of action of the antihypertensive classes used in ASCOT-BPLA, why might the atenolol and bendroflumethiazide combination lead to a higher incidence of new-onset diabetes compared to amlodipine and perindopril?
Key Response
Beta-blockers like atenolol can decrease insulin sensitivity and inhibit insulin release from pancreatic beta cells, which is partly beta-2 mediated. Thiazides like bendroflumethiazide can cause hypokalemia, which impairs insulin secretion. Together, they exert a synergistic dysmetabolic effect, increasing the risk of new-onset diabetes, unlike the metabolically neutral or protective CCB and ACE-inhibitor combination.
A 60-year-old patient with newly diagnosed uncomplicated hypertension presents for treatment initiation. Historically, beta-blockers were often used first-line. Based on the ASCOT-BPLA results, why would an amlodipine or perindopril-based regimen be preferred over an atenolol-based regimen for this patient?
Key Response
ASCOT-BPLA demonstrated that an amlodipine-based regimen with perindopril was superior to an atenolol-based regimen with bendroflumethiazide in reducing major cardiovascular events, strokes, and all-cause mortality, while also reducing the risk of new-onset diabetes. Consequently, beta-blockers are no longer recommended as first-line therapy for uncomplicated hypertension unless there is a compelling indication such as heart failure or post-myocardial infarction.
The ASCOT-BPLA trial found significant differences in cardiovascular outcomes despite relatively small differences in brachial blood pressure between the two arms. How did the ASCOT-CAFE substudy help explain this discrepancy, and what does it teach us about the pharmacology of these drug classes?
Key Response
The Conduit Artery Function Evaluation or CAFE substudy showed that although brachial peripheral blood pressures were similar, the amlodipine and perindopril regimen significantly lowered central aortic pressures compared to the atenolol and thiazide regimen. Beta-blockers lower heart rate, increasing the duration of systole and allowing the reflected arterial wave to augment central systolic pressure, which correlates better with cardiovascular outcomes than peripheral pressure.
ASCOT-BPLA was stopped early due to significant mortality benefits in the amlodipine-based arm. When mentoring junior clinicians on rational polypharmacy for hypertension, how does the synergistic combination of a CCB and an ACE inhibitor used in this trial optimize efficacy while minimizing specific side effects?
Key Response
Amlodipine, a dihydropyridine CCB, acts as a potent precapillary arterial vasodilator, which can lead to increased hydrostatic pressure in the capillaries and subsequent peripheral edema. Adding an ACE inhibitor like perindopril causes postcapillary venodilation, normalizing the transcapillary pressure gradient and significantly reducing the incidence of CCB-induced peripheral edema while providing synergistic blood pressure lowering.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ASCOT-BPLA trial utilized a PROBE, Prospective Randomized Open-label Blinded Endpoint, design rather than a traditional double-blind design. What are the methodological advantages and potential sources of bias inherent in the PROBE design for a large pragmatic trial of this nature?
Key Response
The PROBE design allows for more real-world, pragmatic dose titration and reflects standard clinical practice better than a double-blind design, while significantly reducing trial costs. However, the open-label nature introduces potential investigator bias in adjusting concurrent medications and can influence subjective adverse event reporting, although blinding the endpoint adjudication committee mitigates detection bias for primary hard clinical outcomes.
As a peer reviewer evaluating the ASCOT-BPLA manuscript, how would you scrutinize the 2.7/1.9 mmHg lower mean blood pressure achieved in the amlodipine-based arm compared to the atenolol-based arm, and what threat does this pose to the study conclusions?
Key Response
A rigorous reviewer would flag that even small differences in blood pressure can account for significant variations in stroke and cardiovascular events over a long follow-up period. While statistical adjustments suggested the BP difference did not fully explain the benefit, it remains a significant threat to internal validity, raising the question of whether the drugs themselves are superior or simply the degree of BP control achieved.
The ASCOT-BPLA trial was instrumental in changing global hypertension guidelines. How did the results of this trial directly influence the positioning of beta-blockers in the 2017 ACC/AHA and 2018 ESC/ESH hypertension guidelines?
Key Response
ASCOT-BPLA provided definitive evidence that traditional beta-blockers combined with thiazides offer inferior protection against stroke and mortality, and higher rates of incident diabetes, compared to CCB and ACEI combinations. Consequently, current ACC/AHA and ESC/ESH guidelines relegated beta-blockers from first-line status for uncomplicated hypertension, reserving them for compelling indications like ischemic heart disease or heart failure with reduced ejection fraction.
Clinical Landscape
Noteworthy Related Trials
ALLHAT Trial
Tested
Amlodipine or lisinopril
Population
Hypertensive patients with at least one other CHD risk factor
Comparator
Chlorthalidone
Endpoint
Fatal CHD or nonfatal MI
LIFE Trial
Tested
Losartan-based regimen
Population
Hypertensive patients with left ventricular hypertrophy
Comparator
Atenolol-based regimen
Endpoint
Composite of CV death, MI, and stroke
ACCOMPLISH Trial
Tested
Benazepril plus amlodipine
Population
High-risk hypertensive patients
Comparator
Benazepril plus hydrochlorothiazide
Endpoint
Composite of CV death, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitated cardiac arrest, or coronary revascularization
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis